Why markets already priced in a vaccine approval, stellar gains from AIM stocks in 2020, retail’s latest challenge and dealing with NS&I’s punishing rate cuts
The UK’s status as the first country in the world to approve Pfizer’s Covid vaccine failed to move stock markets on the day of the news. Listen to the podcast to find out why markets reacted in this way.
Tom Sieber from Shares magazine joins the show to discuss the reasons why the AIM market has done nearly as well as the US S&P 500 in 2020 and significantly outperformed large cap UK stocks in the FTSE 100.
The podcast looks at the large rate cuts on NS&I accounts and what savers can do to improve their situation. And the team also debate the latest in the retail sector after Debenham’s struggles and Arcadia going into administration.
Presented by AJ Bell’s Dan Coatsworth and Laith Khalaf
Latest podcasts:
Helping women's careers with Smart Works
On this episode of the AJ Bell Money Matters podcast, Danni and Laura discuss common financial changes in the summer months with both of them on the cusp of... Read more
Money Matters Podcast | Wed, 30/07/2025 - 08:12
In this week’s Money and Markets podcast, Tom Sieber and Charlene Young discuss the latest twist in the tariffs saga as the US and Japan announce a deal and... Read more
Money & Markets Podcast | Fri, 25/07/2025 - 09:07
In this week’s AJ Bell Money and Markets podcast, Laith Khalaf and Tom Selby dive into what’s been moving in markets, from the... Read more
Money & Markets Podcast | Thu, 17/07/2025 - 09:53